A practical reference on Research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The cancerous skin lesions refer to damaged cutaneous tissues with risks of further developing into skin cell carcinoma. Skin carcinoma, or skin cancer, is very common in sun-radiation-abundant areas. The over-exposure to sunlight is the most prevalent cause that leads to Actinic keratosis (AK), a common cancerous cutaneous lesion. Photodynamic therapy (PDT) has proven to be an effective approach for AK at sites of poor healing with few responses to other therapies. In the comparison study between MAL-LEDT and typical cryotherapy, blue-light LEDT with Aminolevulinic acid (ALA) as a photosensitizer reveals significantly higher healing rates. The other clinical trial illustrates the effect of combined therapy of red-light LEDT and nano-emulsion in treating cancerous skin lesions.
Silver sulfadiazine, sold under the brand Silvadene among others, is a topical antibiotic used in partial thickness (second-degree) and full thickness (third-degree) burns to prevent infection. Tentative evidence has found other antibiotics to be more effective, and therefore it is no longer generally recommended for second-degree burns, but is still widely used to protect third-degree burns. Common side effects include itching and pain at the site of use. Other side effects include low white blood cell levels, allergic reactions, bluish grey discoloration of the skin, red blood cell breakdown, or liver inflammation. Caution should be used in those allergic to other sulfonamides. It should not be used in pregnant women who are close to delivery. It is not recommended for use in children less than two months of age. Silver sulfadiazine was first described in 1943 as the precipitate formed from reacting sodium sulfadiazine with silver nitrate in water, and rediscovered in the 1960s as a topical treatment for burns. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 279th most commonly prescribed medication in the United States, with more than 700,000 prescriptions.
A power supply issue at Thames Water's west London treatment works leaves thousands of properties in south west London without water or with low water pressure. 14 September – Health Secretary Steve Barclay gives his backing to the introduction of Martha's Rule to hospitals in England, where patients are made aware that they are entitled to a second opinion. NHS England will also begin implementing the rule. The Metropolitan Police have paid damages to two women who were arrested at a vigil for Sarah Everard, who was murdered by a serving police officer in March 2021. 15 September – Three people appear in court charged with the murder of Sara Sharif, and are remanded in custody. The Metropolitan Police apologises and agrees to pay compensation to Alfie Meadows, who sustained brain injuries after being hit with a baton by a police officer during the 2010 student protests. 16 September – A man is arrested in the Royal Mews near Buckingham Palace following reports of someone climbing a wall in the area; he is detained under the Serious Organised Crime and Police Act on suspicion of trespassing. 17 September – Heavy rain causes flash flooding in Kenton, Devon. 19 September – The UK government announces that commissioners will be appointed to oversee the running of Birmingham City Council following its recent financial troubles. 21 September – During a hearing at the Old Bailey, Daniel Khalife pleads not guilty to escaping from Wandsworth Prison. 22 September – Surrey Police release new pictures of Sara Sharif as they appeal for more information about her.
Sources: en.wikipedia.org
Since independence due to the partition of India, urbanisation has surged for various reasons. In the south, Karachi stands as the most populous commercial hub along the Indus River. In the east, west, and north, a dense population arc spans cities like Lahore, Faisalabad, Rawalpindi, Islamabad, Sargodha, Gujranwala, Sialkot, Gujrat, Jhelum, Sheikhupura, Nowshera, Mardan, and Peshawar. By 1990–2008, city dwellers constituted 36% of Pakistan's population, making it South Asia's most urbanised nation, with over 50% living in towns of 5,000+ inhabitants. Immigration, both domestic and international, significantly fuels urban growth. Migration from India, especially to Karachi, the largest metropolis, and from nearby countries, accelerates urbanisation, posing new political and socio-economic challenges. Economic shifts like the green revolution and political developments also play crucial roles.
== Society and culture == Shortages of medical calcium gluconate were reported in November 2012 and November 2015 in the United States. Historically, intravenous calcium gluconate was used as an antidote for black widow spider envenomation, often in conjunction with muscle relaxants. This therapy, however, has since been shown to be ineffective.
For height finding, the operator instead connected two antennas at different heights and carried out the same basic operation to determine the vertical angle. Because the transmitter antenna was deliberately focused vertically to improve gain, a single pair of such antennas would only cover a thin vertical angle. A series of such antennas was used, each pair with a different centre angle, providing continuous coverage from about 2.5 degrees over the horizon to as much as 40 degrees above it. With this addition, the final remaining piece of Watt's original memo was accomplished and the system was ready to go into production. Industry partners were canvassed in early 1937, and a production network was organized covering many companies. Metropolitan-Vickers took over design and production of the transmitters, AC Cossor did the same for the receivers, the Radio Transmission Equipment Company worked on the goniometers, and the antennas were designed by a joint AMES-GPO group. The Treasury gave approval for full-scale deployment in August, and the first production contracts were sent out for 20 sets in November, at a total cost of £380,000. Installation of 15 of these sets was carried out in 1937 and 1938. In June 1938 a London headquarters was established to organize the rapidly growing force. This became the Directorate of Communications Development (DCD), with Watt named as the director. Wilkins followed him to the DCD, and A. P. Rowe took over AMES at Bawdsey.
Sources: en.wikipedia.org
can be easily calculated without the need of calibration or gas standards. Furthermore, it gets obvious that the overall sensitivity of a PTR-MS instrument is dependent on the reagent ion yield. Fig. 1 gives an overview of several published (in peer-reviewed journals) reagent ion yields during the last decades and the corresponding sensitivities.
== Contraindications == Nitrovasodilators are contraindicated under circumstances where lowering of blood pressure can be dangerous. This includes, with some variation between the individual substances, severe hypotension (low blood pressure), shock including cardiogenic shock, and anaemia. Whether a specific drug is useful or harmful under heart failure and myocardial infarction depends on its speed of action: Fast acting substances such as glyceryl trinitrate and nitroprusside can be helpful for controlling blood pressure and consequently the amount of blood the heart has to pump, if the application is monitored continuously. Slow acting substances would hold the danger of ischaemia due to an uncontrollably low blood pressure and are therefore contraindicated. Depending on the circumstances, even fast acting substances can be contraindicated – for example, glyceryl trinitrate in patients with obstructive heart failure. These drugs are also contraindicated in patients that have recently taken PDE5 inhibitors such as sildenafil (Viagra).
A definitive diagnosis is made after based on growth hormone concentrations or increased IGF-1 levels. In male dogs with no history of progestogen administration the possibility of a pituitary tumour needs to be examined via CT/MRI. In cats with difficult to manage diabetes but no other signs of hypersomatotropism, the potential for other causes of poor glycaemic control need to be considered.
=== Differential diagnosis === The clinical criteria of meeting a polymyositis diagnosis are non-specific, and a plethora of disorders can present with similar findings such as proximal muscle weakness, changes in lab findings (like an increase in creatine kinase), EMG findings, and muscle biopsy results. The following categories summarize common and uncommon alternative diagnoses, but this list is not exhaustive.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.